key: cord-0808593-tgzfl8to
authors: Connell, Nathan T.; Battinelli, Elisabeth M.; Connors, Jean M.
title: Coagulopathy of COVID‐19 and antiphospholipid antibodies
date: 2020-05-28
journal: J Thromb Haemost
DOI: 10.1111/jth.14893
sha: 0cbb0d4d0807121001fe5a335b9a230158c7fcb5
doc_id: 808593
cord_uid: tgzfl8to

Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-β2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-β2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported.

tion, especially during infection. 3, 4 Whether the IgA isotype alone, noted by Zhang and colleagues, invokes thrombosis remains controversial, with only high titer IgG and IgM isotypes included as diagnostic criteria for the antiphospholipid syndrome. 5 Lack of IgG and/ or IgM titers in these case series precludes any evaluation of their role in the thrombotic sequelae described. 

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Antiphospholipid antibodies and infections

Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects

14th International congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends

Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia